Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 11Thoracic 8CNS 6Gastrointestinal 4Genitourinary 3Breast 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Prostatic Neoplasms 2Carcinoma, Renal Cell 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × enzastaurin × Genitourinary × Clear all
NCT00428714 2020-11-25

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Eli Lilly and Company

Phase 2 Completed
73 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT00466440 2020-11-06

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

Eli Lilly and Company

Phase 2 Completed
108 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

NCT00709995 2019-09-30

A Study for Participants With Metastatic Renal Cell Carcinoma

Eli Lilly and Company

Phase 2 Completed
17 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡